Who are Remedy Pharmaceuticals's investors?

Remedy Pharmaceuticals's investors include Broadview Ventures, The Vertical Group.

How much funding has Remedy Pharmaceuticals raised?

Remedy Pharmaceuticals has disclosed $10.9M raised across 3 rounds.

Where is Remedy Pharmaceuticals headquartered?

Remedy Pharmaceuticals is headquartered in New York, US.

Remedy Pharmaceuticals

New York, US · Delaware corporation · 2 known investors

Remedy Pharmaceuticals is a pharmaceutical company developing Cirara, an investigational drug studied in clinical trials for patients who have suffered a stroke. It focuses on treatments for serious neurological conditions.

Biotech Healthtech

Founders & leadership

SVEN JACOBSONExecutive

DAVID M. GELIEBTERNamed on SEC filing

Board

DAVID GELIEBTERBoard director

Investors · 2

Broadview VenturesBoston

The Vertical GroupBerkeley Heights · $250K – $5M

Reported raises · per SEC filings

Form D private placements

$10.9M disclosed across 3 rounds · 2011–2015

▶$9.1MraisedDec 2015 · 30 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

SVEN JACOBSONExecutive Officer, Director
DAVID GELIEBTERDirector

Offering amount: $9.1M
Amount sold: $9.1M
First sale: Nov 2015
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$1MraisedFeb 2014 · 4 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

SVEN JACOBSONExecutive Officer, Director
DAVID GELIEBTERDirector

Offering amount: $1.4M
Amount sold: $1M
Sales commissions: $10.5K
Placement agents: PERAZA CAPITAL AND INVESTMENT, LLC
First sale: Nov 2013
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$792.5KraisedMar 2012 · 3 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

DAVID M. GELIEBTERDirector
SVEN JACOBSONExecutive Officer, Director

Offering amount: $792.5K
Amount sold: $792.5K
First sale: Oct 2011
Incorporated: Corporation, Delaware
Federal exemptions: 06

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap

Remedy Meds22 shared keywordsRemedy Meds offers personalized medical weight loss treatment using compounded GLP-1 medications (semaglutide and tirzepatide) paired with clinician-led care and support delivered directly to patients. The service targets individuals seeking prescription-based weight loss solutions with ongoing medical supervision and community support.

Companies competing with Remedy Pharmaceuticals for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Remedy Pharmaceuticals Gets Rights To Acute Stroke Drug Back From Biogen; Announces Clinically Meaningful and Statistically Significant Results From Pre-specified Subgroup and Post Hoc Analyses of Phase 3 Studyprnewswire.com · May 2024

Remedy Pharmaceuticals - Green Circle Capitalgreencirclecap.com · Oct 2023

Remedy Pharmaceuticals Completes $9M Financing Round - FinSMEsfinsmes.com · Dec 2015

Frequently asked questions

What does Remedy Pharmaceuticals do?: Remedy Pharmaceuticals is a pharmaceutical company developing Cirara, an investigational drug studied in clinical trials for patients who have suffered a stroke. It focuses on treatments for serious neurological conditions.
Who are Remedy Pharmaceuticals's investors?: Remedy Pharmaceuticals's investors include Broadview Ventures, The Vertical Group.
How much funding has Remedy Pharmaceuticals raised?: Remedy Pharmaceuticals has disclosed $10.9M raised across 3 rounds.
Where is Remedy Pharmaceuticals headquartered?: Remedy Pharmaceuticals is headquartered in New York, US.